Molecular and Functional Noninvasive Immune Monitoring in the ESCAPE Study for Prediction of Subclinical Renal Allograft Rejection
Authors:
- Silke RoedderSRSilke Roedder
- Tara SigdelTSTara Sigdel
- Szu-Chuan HsiehSHSzu-Chuan Hsieh
- Sergio LuqueSLSergio Luque
- Josep Maria CruzadoJCJosep Maria Cruzado
- Tim Q. TranTTTim Q. Tran
- Josep Maria GrinyóJGJosep Maria Grinyó
- Minnie M. SarwalMSMinnie M. Sarwal
- Oriol BestardOBOriol Bestard
- 1 June 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 101 (6) , 1400-1409
Abstract
Subclinical acute rejection (sc-AR) is a main cause for functional decline and kidney graft loss and may only be assessed through surveillance biopsies. The predictive capacity of 2 novel noninvasive blood biomarkers, the transcriptional kidney Solid Organ Response Test (kSORT), and the IFN-γ enzyme-linked immunosorbent spot assay (ELISPOT) assay were assessed in the Evaluation of Sub-Clinical Acute rejection PrEdiction (ESCAPE) Study in 75 consecutive kidney transplants who received 6-month protocol biopsies. Both assays were run individually and in combination to optimize the use of these techniques to predict sc-AR risk. Subclinical acute rejection was observed in 22 (29.3%) patients (17 T cell–mediated subclinical rejection [sc-TCMR], 5 antibody-mediated subclinical rejection [sc-ABMR]), whereas 53 (70.7%) showed a noninjured, preserved (stable [STA]) parenchyma. High-risk (HR), low-risk, and indeterminate-risk kSORT scores were observed in 15 (20%), 50 (66.7%), and 10 (13.3%) patients, respectively. The ELISPOT assay was positive in 31 (41%) and negative in 44 (58.7%) patients. The kSORT assay showed high accuracy predicting sc-AR (specificity, 98%; positive predictive value 93%) (all sc-ABMR and 58% sc-TCMR showed HR-kSORT), whereas the ELISPOT showed high precision ruling out sc-TCMR (specificity = 70%, negative predictive value = 92.5%), but could not predict sc-ABMR, unlike kSORT. The predictive probabilities for sc-AR, sc-TCMR, and sc-ABMR were significantly higher when combining both biomarkers (area under the curve > 0.85, P < 0.001) and independently predicted the risk of 6-month sc-AR in a multivariate regression analysis. Combining a molecular and immune cell functional assay may help to identify HR patients for sc-AR, distinguishing between different driving alloimmune effector mechanisms.Keywords
This publication has 25 references indexed in Scilit:
- Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney AllograftsJournal of the American Society of Nephrology, 2015
- Antibody-mediated rejection in young kidney transplant recipients: the dilemma of noncompliance and insufficient immunosuppressionPediatric Nephrology, 2014
- The kSORT Assay to Detect Renal Transplant Patients at High Risk for Acute Rejection: Results of the Multicenter AART StudyPLOS Medicine, 2014
- Biomarkers for kidney transplant rejectionNature Reviews Nephrology, 2014
- A Peripheral Blood Diagnostic Test for Acute Rejection in Renal TransplantationAmerican Journal of Transplantation, 2012
- Detection of Clinical and Subclinical Tubulo-Interstitial Inflammation by the Urinary CXCL10 Chemokine in a Real-Life SettingAmerican Journal of Transplantation, 2012
- Surveillance Protocol Kidney Transplant Biopsies: Their Evolving Role in Clinical PracticeAmerican Journal of Transplantation, 2011
- To Biopsy or Not to Biopsy? Should We Screen the Histology of Stable Renal Grafts?Transplantation, 2007
- Subclinical Rejection Associated with Chronic Allograft Nephropathy in Protocol Biopsies as a Risk Factor for Late Graft LossAmerican Journal of Transplantation, 2006
- Predicting Subsequent Decline in Kidney Allograft Function from Early Surveillance BiopsiesAmerican Journal of Transplantation, 2005